About Sergio Traversa
Sergio Traversa is a chief executive officer and director at Relmada Therapeutics.
Form D filings name Sergio Traversa as a director at EnZeta Immunotherapies.
Sergio Traversa reports to the SEC as a director or officer of 2 public companies, including Actinium Pharmaceuticals (ATNM).
Sergio Traversa first appears on SEC filings in 2013.
Experience
This experience comes from Sergio Traversa's profile and from SEC filings. For roles taken from filings, the years are when the filings name Sergio Traversa in the role, so the role may have started earlier or lasted longer.
RI
Relmada Therapeutics, Inc. Current
CEO (2012 – Present)
Director
2012 – Present · Public company (RLMD)
AI
Actinium Pharmaceuticals, Inc.
Interim CFO and director
2013 – 2017 · Public company (ATNM)
MT
Medeor Inc., acquired by Relmada Therapeutics
CEO
2010 – 2011
AC
Ardana Capital
Chief Investment Officer
2007 – 2009
RM
Rx Capital Management
Pharmaceutical analyst
2002 – 2006
MG
Merlin BioMed Group
Portfolio Manager, pharmaceutical
2001 – 2002
IB
ING Barings
Managing Director, Pharmaceutical Equity Research
2000 – 2001
MI
Mehta and Isaly
Pharmaceutical analyst
1996 – 2000
JJ
Johnson & Johnson
Country Manager, Southern Europe
1995 – 1996
EL
Eli Lilly
Hospital Unit Manager, Italy
1988 – 1993
FE
Farmitalia Carlo Erba
Sales representative
1986 – 1988
Key Colleagues at Startups
The people Sergio Traversa works with at each company, as listed on that company's latest Form D.
EnZeta Immunotherapies, Inc. · Form D/A, Mar 6, 2026
PK
Paul Kelly
President and director